L&C Bio Co. Ltd
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.
L&C Bio Co. Ltd (290650) - Total Assets
Latest total assets as of September 2025: ₩497.94 Billion KRW
Based on the latest financial reports, L&C Bio Co. Ltd (290650) holds total assets worth ₩497.94 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
L&C Bio Co. Ltd - Total Assets Trend (2015–2024)
This chart illustrates how L&C Bio Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
L&C Bio Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
L&C Bio Co. Ltd's total assets of ₩497.94 Billion consist of 27.4% current assets and 72.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩18.29 Billion | 3.8% |
| Accounts Receivable | ₩21.73 Billion | 4.6% |
| Inventory | ₩46.78 Billion | 9.8% |
| Property, Plant & Equipment | ₩97.02 Billion | 20.4% |
| Intangible Assets | ₩1.93 Billion | 0.4% |
| Goodwill | ₩197.31 Billion | 41.5% |
Asset Composition Trend (2015–2024)
This chart illustrates how L&C Bio Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: L&C Bio Co. Ltd's current assets represent 27.4% of total assets in 2024, a decrease from 83.5% in 2015.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2024, down from 6.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 41.5% of total assets.
L&C Bio Co. Ltd Competitors by Total Assets
Key competitors of L&C Bio Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
L&C Bio Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - L&C Bio Co. Ltd generates 0.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, L&C Bio Co. Ltd generates $ 29.66 in net profit.
L&C Bio Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.70 | 1.11 | 12.38 |
| Quick Ratio | 0.47 | 0.57 | 10.18 |
| Cash Ratio | 0.00 | 0.23 | 0.00 |
| Working Capital | ₩-62.47 Billion | ₩ 10.16 Billion | ₩ 41.83 Billion |
L&C Bio Co. Ltd - Advanced Valuation Insights
This section examines the relationship between L&C Bio Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.10 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 81.4% |
| Total Assets | ₩475.60 Billion |
| Market Capitalization | $840.69 Million USD |
Valuation Analysis
Below Book Valuation: The market values L&C Bio Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: L&C Bio Co. Ltd's assets grew by 81.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for L&C Bio Co. Ltd (2015–2024)
The table below shows the annual total assets of L&C Bio Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩475.60 Billion | +81.37% |
| 2023-12-31 | ₩262.23 Billion | +31.30% |
| 2022-12-31 | ₩199.73 Billion | +85.96% |
| 2021-12-31 | ₩107.40 Billion | +33.29% |
| 2020-12-31 | ₩80.58 Billion | +21.67% |
| 2019-12-31 | ₩66.23 Billion | +15.42% |
| 2018-12-31 | ₩57.38 Billion | +180.03% |
| 2017-12-31 | ₩20.49 Billion | +30.84% |
| 2016-12-31 | ₩15.66 Billion | +71.88% |
| 2015-12-31 | ₩9.11 Billion | -- |